CVSIOTCPharmaceutical PreparationsFiscal year ends December 31
CV Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.01−0.00 (-21.13%)
Close on Oct 19, 2026
- Market cap
- $2.30M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
49.0%+3.9 pts over 5 years
Operating margin
-3.4%+89.1 pts over 5 years
Net margin
-6.9%+84.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -12.2% | -5.2% | -10.8% | +1.8% | |
| Gross profit | -5.8% | +6.8% | -9.3% | +0.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -77.5% | -110.4% | -58.7% | |
| Return on assets | -61.6% | -53.5% | -12.9% | |
| Current ratio | 1.53 | 1.18 | 1.03 | |
| Debt to equity | – | 0.32 | 1.12 | |
| Net debt to EBITDA | – | 0.04× | -4.93× | |
| Interest coverage | -12.0× | – | -0.9× | |
| Inventory turnover | 0.5× | 1.4× | 1.6× | |
| Capex to revenue | 0.2% | 4.3% | 0.8% | |
| Diluted shares | 53M | 100M | 184M |
Where the cash went
Fiscal 2021 to 2025, five years combined
CV Sciences generated $12.89M from operations and spent $162.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$12.89M
Used
$162.00K
Capital expenditure$162.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-6.9%
×Asset turnover1.85×
×Equity multiplier4.56×
=Return on equity, FY2025-58.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -6.9% | 1.85× | 4.56× | -58.7% |
| FY2024 | -15.2% | 1.83× | 3.65× | -101.9% |
| FY2023 | 19.4% | 1.46× | 10.32× | 291.8% |
| FY2022 | -50.7% | 1.05× | 11.14× | -593.9% |
| FY2021 | -77.6% | 0.82× | 3.30× | -210.8% |
| FY2020 | -91.2% | 0.59× | 2.06× | -110.4% |
| FY2019 | -30.9% | 1.20× | 1.51× | -56.1% |
| FY2018 | 20.7% | 1.62× | 1.28× | 43.0% |
| FY2017 | -23.7% | 1.00× | 1.40× | -33.1% |
| FY2016 | -127.9% | 0.48× | 1.26× | -77.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$958.00K
- Cash generatingOperating cash flow above zero-$407.00K
- Return on assets improvedROA up on the prior year-26.0% → -12.1%
- Earnings backed by cashOperating cash flow above net income-$407.00K vs -$958.00K
- Less leverageLong-term debt to assets fell0.0% → 5.6%
- Better liquidityCurrent ratio rose1.02 → 1.03
- No dilutionShare count did not rise176M → 184M
- Gross margin improvedGross margin up on the prior year45.64% → 48.97%
- More efficientAsset turnover rose1.71 → 1.74